Severe COPD therapy reference (2026)

Severe COPD therapy in 2026 organises around foundational, biologic, and emerging tiers.

Foundational inhaler therapy: dual or triple long-acting bronchodilator therapy is standard for symptomatic patients. Long-acting beta-agonist (LABA) plus long-acting muscarinic antagonist (LAMA) plus inhaled corticosteroid (ICS) triple therapy is preferred for patients with frequent exacerbations or eosinophilic phenotype. Multiple combination products simplify delivery.

Non-pharmacological foundation: smoking cessation is essential. Pulmonary rehabilitation, vaccination (influenza, pneumococcal, RSV, COVID), oxygen therapy in qualifying patients, and non-invasive ventilation in selected patients all contribute.

For frequent exacerbators on optimal inhaler therapy:

Chronic macrolide (azithromycin) reduces exacerbation frequency. Roflumilast is an oral PDE4 inhibitor option in selected patients with chronic bronchitis phenotype.

Biologic therapy: dupilumab carries COPD approval in patients with eosinophilic phenotype and persistent exacerbations on optimal inhaler therapy. Mepolizumab and benralizumab pivotal data in COPD eosinophilic phenotype is reading out. The biomarker-pathway question (blood eosinophil count, FeNO, biomarker-defined phenotyping) shapes biologic selection.

Emerging mechanism class: ensifentrine (inhaled PDE3/PDE4 inhibitor) provides a new mechanism class added on top of bronchodilator therapy. Additional biologic programs and oral mechanism-targeted programs in late-stage trials.

The diagnostic-pathway question matters. Spirometry-confirmed COPD diagnosis, structured exacerbation history, and biomarker-defined phenotyping shape modern severe COPD therapy selection.